← Back to Search

Prostacyclin Analogue

Inhaled treprostinil solution for Chronic Obstructive Pulmonary Disease (PERFECT Trial)

Phase 3
Waitlist Available
Research Sponsored by United Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 12
Awards & highlights

PERFECT Trial Summary

This trial is testing if inhaled treprostinil can help improve exercise ability in people with PH-COPD, as measured by how far they can walk in 6 minutes.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Hypertension

PERFECT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline to Week 12 in 6-Minute Walk Distance (6MWD)
Secondary outcome measures
Change From Baseline to Week 12 in 6MWD/Borg Dyspnea Composite Score
Change From Baseline to Week 12 in Borg Dyspnea Score
Change From Baseline to Week 12 in Moderate to Vigorous Physical Activity (MVPA)
+5 more

PERFECT Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Inhaled TreprostinilExperimental Treatment1 Intervention
Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms [mcg]) 4 times daily (QID)
Group II: PlaceboPlacebo Group1 Intervention
Placebo delivered via an ultrasonic nebulizer for QID administration

Find a Location

Who is running the clinical trial?

United TherapeuticsLead Sponsor
107 Previous Clinical Trials
13,199 Total Patients Enrolled
Medical DirectorStudy DirectorUnited Therapeutics
2,777 Previous Clinical Trials
8,063,676 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any harmful effects to inhaling treprostinil solution?

"There is some clinical evidence to support inhaled treprostinil solution's efficacy, so it received a score of 3."

Answered by AI

If Inhaled treprostinil solution has undergone clinical trials before, where can I find information about those?

"inhaled treprostinil solution was first studied in the year 2015 at Arkansas Children's Hospital. So far, there have been 69 completed trials and 9 that are still recruiting participants. Most of these active studies are based in Boston, Massachusetts."

Answered by AI

What are the primary conditions that Inhaled treprostinil solution has been shown to improve?

"Treprostinil solution, which is delivered through inhalation, is most often used to improve the symptoms of patients with Nyha functional class III pulmonary arterial hypertension. Additionally, this medication can be given to patients suffering from other conditions like WHO functional class II-III pulmonary arterial hypertension."

Answered by AI

Who else is applying?

What state do they live in?
Florida
Virginia
Other
California
How old are they?
65+
What portion of applicants met pre-screening criteria?
Met criteria
What site did they apply to?
University of Illinois Medical Center
~27 spots leftby Apr 2025